Dr. Tyna Moore · 2026-03-05 · Tyna Moore (host), Natalie Jill
Stop Dieting Like It’s 1995: Midlife Fat Loss Looks Different Now | Natalie Jill
19 research-tied claims examined: 5 contradicted 6 context 7 supported 1 unverified
7 Supported by research
Muscle tissue burns more calories at rest than fat tissue, meaning having more muscle increases resting metabolic rate.
"The more muscle you have, the more calories you burn at rest. So, just sitting here because I have more muscle, just you sitting here because you have more muscle, we are burning more calories at rest." (said at 0:00:00)
Published human body composition and indirect calorimetry studies confirm that skeletal muscle tissue has a higher specific metabolic rate at rest than adipose tissue (approximately 13 kcal/kg/day versus 4.5 kcal/kg/day). Because of this difference and the large total mass of skeletal muscle, having greater muscle mass increases whole-body resting metabolic rate (resting energy expenditure).
- supports: Effect of organ and tissue masses on resting energy expenditure in underweight, normal wei… (International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity 2004) · cited 141x in the literature
"In a multiple regression analysis, MM and liver mass explained 81% of the variance in REEm. DXA-derived REE prediction showed a good agreement with measured values" (abstract, results, passage verified)
pubmedfull study (doi) - supports: Advances in the understanding of specific metabolic rates of major organs and tissues in h… (Current opinion in clinical nutrition and metabolic care 2013) · cited 94x in the literature
"In humans, present knowledge on specific metabolic activities (i.e. ki-values) refers to seven organs and tissues - brain, heart, liver, kidneys, skeletal muscle, adipose tissue and residual mass - with ki-values of 240, 440, 200, 440, 13, 4.5 and 12 kcal/kg/day, provided by Elia in 1992." (abstract, results, passage verified)
pubmedfull study (doi)
GLP-1 receptor agonist therapy improves sex hormone profiles in individuals who are obese and severely metabolically compromised.
"and we're starting to see these in the studies that when you go into a GLP-1 journey at a regular dose and you are obese and you're severely metabolically compromised, it will improve your hormonal profile." (said at 0:21:20)
Published systematic reviews and meta-analyses support that GLP-1 receptor agonists (such as semaglutide and liraglutide) improve sex hormone profiles in individuals with obesity and metabolic dysfunction. In men with obesity, type 2 diabetes, or metabolic hypogonadism, GLP-1 receptor agonist therapy is associated with significant increases in total and bioavailable testosterone concentrations while preserving gonadotropin function. In women with obesity and polycystic ovary syndrome (PCOS), meta-analyses of randomized controlled trials demonstrate that GLP-1 receptor agonists significantly reduce elevated total testosterone and improve markers of hyperandrogenism alongside weight loss and glycemic improvements.
- supports: The efficacy and safety of GLP-1 agonists in PCOS women living with obesity in promoting w… (Journal of diabetes and its complications 2024) · cited 61x in the literature
"GLP1-RAs use was associated with a significant reduction in waist circumference (MD: -5.16 cm; 95 % CI: -6.11 to -4.21; p ˂ 0.00001), body mass index (BMI) (MD: -2.42; 95 % CI: -3.10 to -1.74; p ˂ 0.00001), serum triglycerides (MD: -0.20; 95 % CI: -0.30 to -0.11; p ˂ 0.00001) and total testosterone levels (MD: -1.33; 95 % CI: -2.55 to -0.12; p = 0.03) when compared to placebo." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Effect of GLP-1 agonists on testosterone levels: a systematic review and meta-analysis. (BMC urology 2025) · cited 5x in the literature
"GLP-1 RA use was significantly associated with increased bioavailable testosterone (MD -57.18; 95% CI -87.60 to -26.76; p < 0.001; I 2 = 86%) and decreased HbA1c (MD 0.79; 95% CI 0.58 to 1.00; p < 0.001; I 2 = 0%)." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Effects of glucagon-like peptide-1 receptor agonists on male reproductive hormones, semen … (The journal of sexual medicine 2026) · cited 8x in the literature
"GLP-1RAs were consistently associated with increased total testosterone, particularly in men with obesity, type 2 diabetes, or functional hypogonadism. Free testosterone changes were inconsistent, often offset by concurrent rises in sex hormone-binding globulin. Luteinizing hormone and follicle-stimulating hormone levels were preserved or increased with GLP-1RA use, in contrast to the suppression observed in testosterone therapy comparator groups." (abstract, results, passage verified)
pubmedfull study (doi)
Nighttime artificial lighting and lack of daytime sun exposure disrupt cortisol levels and sleep.
"Like when the sun sets, we don't have overhead LEDs on at all... But light really affects your cortisol levels. Really affects your sleep." (said at 0:45:58)
Light exposure, particularly its timing and spectral composition (such as short-wavelength blue light), exerts a direct influence on hypothalamic-pituitary-adrenal (HPA) axis activity, cortisol secretion, and sleep architecture. Systematic reviews and controlled laboratory trials demonstrate that nocturnal or late-evening exposure to bright or blue-enriched artificial light alters cortisol secretion dynamics, attenuates the cortisol awakening response, suppresses melatonin, and disrupts slow-wave sleep and subjective sleepiness.
- supports: Characterizing the temporal Dynamics of Melatonin and Cortisol Changes in Response to Noct… (Scientific reports 2019) · cited 66x in the literature
"There was a significant linear increase of cortisol levels between the start and end of each IBL stimulus. Under CBL conditions cortisol showed trimodal changes with an initial linear activating phase, followed by an exponential inhibitory phase, and a final exponential recovery phase. These results show that light exposure at night affects circadian driven hormones differently and that outcomes are influenced by the duration and pattern of light exposure." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Preliminary Results: The Impact of Smartphone Use and Short-Wavelength Light during the Ev… (Clocks & sleep 2021) · cited 62x in the literature
"Cortisol was elevated in the morning after reading on the smartphone without a filter, which resulted in a reduced cortisol awakening response... Early slow wave sleep/activity and objective alertness in the morning were only reduced after reading without a filter. These results indicate that short-wavelength light affects not only circadian rhythm and evening sleepiness but causes further effects on sleep physiology and alertness in the morning." (abstract, results)
pubmedfull study (doi) - supports: The Influence of Light Wavelength on Human HPA Axis Rhythms: A Systematic Review. (Life (Basel, Switzerland) 2023) · cited 34x in the literature
"An analysis of the literature indicated that exposure to bright lights of any colour during the late night or early morning can induce significant increases in cortisol secretion relative to time-matched dim light comparison conditions. Furthermore, exposure to bright lights with stronger short-wavelength (blue/green) components in the early morning typically induced greater increases in cortisol relative to lights with stronger long-wavelength (red) components. Thus, the circadian regulation of cortisol is sensitive to the wavelength composition of environmental lighting, in line with the more commonly studied melatonin." (abstract, results, passage verified)
pubmedfull study (doi)
GLP-1 receptor agonist medications significantly reduce systemic inflammation.
"it does significantly decrease inflammation." (said at 0:58:41)
High-certainty evidence from multiple systematic reviews and meta-analyses of randomized controlled trials (RCTs) confirms that GLP-1 receptor agonist medications significantly decrease systemic inflammation. Meta-analyses consistently demonstrate significant reductions in primary systemic inflammatory biomarkers, most notably C-reactive protein (CRP/hs-CRP) and tumor necrosis factor-alpha (TNF-α), in patients treated with GLP-1 receptor agonists compared to placebo or active controls, across populations with type 2 diabetes mellitus and/or obesity.
- supports: Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis. (Frontiers in cardiovascular medicine 2024) · cited 51x in the literature
"Overall, semaglutide therapy was associated with lower CRP index values compared to the placebo group (SMD -0.56; 95% CI -0.69 to -0.43, I 2 92%) or the control group (SMD -0.45; 95% CI -0.68 to -0.23, I 2 82%).Such an association was similarly observed when different treatment regimens (subcutaneous vs. oral) or different populations (patients with or without T2DM) were analysed." (abstract, results, passage verified)
pubmedfull study (doi) - supports: The effect of GLP-1 receptor agonists on circulating inflammatory markers in type 2 diabet… (Diabetes, obesity & metabolism 2025) · cited 49x in the literature
"GLP-1 RAs treatment, compared to placebo or conventional diabetes therapies (including oral medicine and insulin), resulted in significant reductions in CRP, TNF-α, IL-6, IL-1β and leptin (standard mean difference [SMD] -0.63 [-1.03, -0.23]; SMD -0.92 [-1.57, -0.27]; SMD -0.76 [-1.32, -0.20], SMD -3.89 [-6.56, -1.22], SMD -0.67 [-1.09, -0.26], respectively), as well as significant increases in adiponectin (SMD 0.69 [0.19, 1.19])." (abstract, results, passage verified)
pubmedfull study (doi)
Stimulant ADHD medications are used for weight loss.
"People are using ADHD meds for weight loss." (said at 1:00:59)
Epidemiological surveys and observational studies document that prescription ADHD medications (stimulants such as amphetamine/dextroamphetamine and methylphenidate) are misused or used non-medically specifically for weight loss and appetite suppression. In addition, the ADHD stimulant medication lisdexamfetamine is clinically utilized and approved for moderate-to-severe binge-eating disorder, where weight reduction is a documented outcome.
Declining estrogen levels can contribute to or cause depression in women.
"If it's starting to lead to depression, that is estrogen leaving the building, and I highly encourage you to seek out help from somebody who knows what they're doing." (said at 1:03:37)
Published systematic reviews and clinical evidence establish that hormonal fluctuations and declining estrogen levels during the menopause transition (perimenopause and early postmenopause) represent a biological window of vulnerability for developing depressive symptoms and major depressive episodes. Estrogen exerts key neuromodulatory effects on central monoaminergic and neuroplastic pathways, and randomized controlled trials demonstrate that exogenous estrogen therapy can improve depressive symptoms in perimenopausal women.
A reduction in estrogen levels causes the diameter of the hair shaft itself to thin.
"I will tell you that estrogen leaving the body causes the hair shaft itself to become thinner. So, it's just the diameter shrinks." (said at 1:03:52)
Estrogen influences hair follicle biology and shaft dimensions. Observational and review literature on menopausal transitions demonstrates that the decline in estrogen levels (such as during menopause) is associated with alterations in hair parameters, including a reduction in hair shaft diameter and shifts in hair diameter distribution leading to hair thinning. Evidence is largely derived from observational studies in women and animal models examining sex hormone status.
Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.